Evidence map›Paper›PMID 40593490›Full record

ArticleNature communications2025

Individualizing glioma radiotherapy planning by optimization of a data and physics-informed discrete loss.

Michal Balcerak, Jonas Weidner, Petr Karnakov, Ivan Ezhov, Sergey Litvinov, Petros Koumoutsakos, Tamaz Amiranashvili, Ray Zirui Zhang, John S Lowengrub, Igor Yakushev and 2 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Inverse Problem Regularization for 3D Multi-Species Tumor Growth Models.International journal for numerical methods in biomedical engineering · 2025
    Article
  5. Deep learning for autosegmentation for radiotherapy treatment planning: State-of-the-art and novel perspectives.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Michal BalcerakDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland. michal.balcerak@uzh.ch.ORCID http://orcid.org/0009-0006-3137-7048
Jonas WeidnerDepartment of Computer Science, Technical University of Munich, Munich, Germany.
Petr KarnakovComputational Science and Engineering Laboratory, Harvard University, Cambridge, MA, USA.
Ivan EzhovDepartment of Computer Science, Technical University of Munich, Munich, Germany.
Sergey LitvinovComputational Science and Engineering Laboratory, Harvard University, Cambridge, MA, USA.
Petros KoumoutsakosComputational Science and Engineering Laboratory, Harvard University, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-8337-2122
Tamaz AmiranashviliDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0001-8914-3427
Ray Zirui ZhangDepartment of Mathematics, University of California, Irvine, CA, USA.
John S LowengrubDepartment of Mathematics, University of California, Irvine, CA, USA.
Igor YakushevDepartment of Nuclear Medicine, Technical University of Munich, Munich, Germany.ORCID http://orcid.org/0000-0003-4764-798X
Benedikt Wiestler *Munich Center for Machine Learning (MCML), Munich, Germany.ORCID http://orcid.org/0000-0002-2963-7772
Bjoern Menze *Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0003-4136-5690

Funding

Simons Foundation QN594598
6 · The paper itself

Abstract

Brain tumor growth is unique to each glioma patient and extends beyond what is visible in imaging scans, infiltrating surrounding brain tissue. Understanding these hidden patient-specific progressions is essential for effective therapies. Current treatment plans for brain tumors, such as radiotherapy, typically involve delineating a uniform margin around the visible tumor on pre-treatment scans to target this invisible tumor growth. This "one size fits all" approach is derived from population studies and often fails to account for the nuances of individual patient conditions. We present the Glioma Optimizing the Discrete Loss (GliODIL) framework, which infers the full spatial distribution of tumor cell concentration from available multi-modal imaging, leveraging a Fisher-Kolmogorov type physics model to describe tumor growth. This is achieved through the newly introduced method of Optimizing the Discrete Loss (ODIL), where both data and physics-based constraints are softly assimilated into the solution. Our test dataset comprises 152 glioblastoma patients with pre-treatment imaging and post-treatment follow-ups for tumor recurrence monitoring. By blending data-driven techniques with physics-based constraints, GliODIL enhances recurrence prediction in radiotherapy planning, challenging traditional uniform margins and strict adherence to the Fisher-Kolmogorov partial differential equation model, which is adapted for complex cases.

Indexed as

Brain NeoplasmsGlioblastomaGliomaRadiotherapy Planning, Computer-AssistedHumansMagnetic Resonance ImagingNeoplasm Recurrence, LocalPrecision Medicine

Identifiers

PMID40593490
PMCPMC12219029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.